Quoin Pharmaceuticals, Ltd.
QNRX
$18.63
-$0.55-2.84%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.44% | 3.99% | -0.74% | -2.71% | -3.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.75% | 41.90% | 21.70% | 1.60% | 1.02% |
| Operating Income | -51.75% | -41.90% | -21.70% | -1.60% | -1.02% |
| Income Before Tax | -58.23% | -47.01% | -24.21% | -3.18% | -0.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.23% | -47.01% | -24.21% | -3.18% | -0.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.23% | -47.01% | -24.21% | -3.18% | -0.73% |
| EBIT | -51.75% | -41.90% | -21.70% | -1.60% | -1.02% |
| EBITDA | -52.32% | -42.40% | -21.98% | -1.66% | -1.07% |
| EPS Basic | 77.46% | 78.57% | 80.80% | 77.40% | 69.22% |
| Normalized Basic EPS | 77.46% | 78.57% | 80.80% | 77.40% | 69.22% |
| EPS Diluted | 77.44% | 78.46% | 80.72% | 77.34% | 69.19% |
| Normalized Diluted EPS | 77.46% | 78.57% | 80.80% | 77.40% | 69.22% |
| Average Basic Shares Outstanding | 417.27% | 477.34% | 633.79% | 421.01% | 337.75% |
| Average Diluted Shares Outstanding | 419.63% | 479.73% | 636.59% | 424.14% | 345.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |